The project had humble beginnings. Back in January 2020 - before, I think, any of us knew the scale of suffering and disruption this virus would bring to this country - you suggested we start a. | June 12, 2021
Howdy, I m Tiff Fehr from the Interactive News team. We are a group of technologists embedded in the newsroom. This has been a significant data-journalism project for The Times,. | June 12, 2021
I m standing here feeling so stunned and grateful to be part of this - but I m also feeling out of sorts, because so many of the brilliant, tireless colleagues who spent last year communicating. | June 12, 2021
Message :
Required fields
April 1 (Reuters) - Johnson & Johnson s
manufacturing partner Emergent Biosolutions said on
Thursday that it had discarded the single batch of COVID-19 drug
substance that did not meet specifications.
J&J on Wednesday said it had found a problem with a batch of
the drug substance for its COVID-19 vaccine being produced at
Emergent s site in Baltimore, Maryland.
The New York Times reported on Wednesday that about 15
million doses were ruined, without citing a source. Discarding a batch of bulk drug substance, while
disappointing, does occasionally happen during vaccine
manufacturing, which is a complex and multi-step biological
process, Emergent said.